Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLewis, A.C.-
dc.contributor.authorWallington-Beddoe, C.T.-
dc.contributor.authorPowell, J.A.-
dc.contributor.authorPitson, S.M.-
dc.identifier.citationCell Death Discovery, 2018; 5(1):4-4-
dc.description.abstractConventional chemotherapy-based drug combinations have, until recently, been the backbone of most therapeutic strategies for cancer. In a time of emerging rationale drug development, targeted therapies are beginning to be added to traditional chemotherapeutics to synergistically enhance clinical responses. Of note, the importance of pro-apoptotic ceramide in mediating the anti-cancer effects of these therapies is becoming more apparent. Furthermore, reduced cellular ceramide in favour of pro-survival sphingolipids correlates with tumorigenesis and most importantly, drug resistance. Thus, agents that manipulate sphingolipid metabolism have been explored as potential anti-cancer agents and have recently demonstrated exciting potential to augment the efficacy of anti-cancer therapeutics. This review examines the biology underpinning these observations and the potential use of sphingolipid manipulating agents in the context of existing and emerging therapies for haematological malignancies.-
dc.description.statementofresponsibilityAlexander C. Lewis, Craig T. Wallington-Beddoe, Jason A. Powell and Stuart M. Pitson-
dc.publisherCell Death Differentiation Association-
dc.rights© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
dc.titleTargeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies-
dc.typeJournal article-
dc.identifier.orcidWallington-Beddoe, C.T. [0000-0002-7457-5937]-
dc.identifier.orcidPitson, S.M. [0000-0002-9527-2740]-
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_117587.pdfPublished version1.05 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.